Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06647329
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-10
Brief Title:
CAR-T Technology for RecurrentRefractory Malignant Hematological and Lymphatic Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
CAR-T Technology for the Treatment of RecurrentRefractory Malignant Hematological and Lymphatic Tumors Multi-Center Clinical Study on Safety and Efficacy
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CAR-T Therapy
Brief Summary:
evaluate the safety and Esfficacy of CAR-T technology for the treatment of recurrentrefractory malignant hematological lymphomas
Detailed Description:
Patients with recurrentrefractory malignant hematological lymphomas were treated with CAR-T technology
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None